3 results match your criteria: "Clinical Hospital of St. Luka[Affiliation]"
[Open observational study with a retrospective analysis of the efficacy and tolerability of aceclofenac in patients with acute non-specific low back pain].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Clinical Hospital of St. Luka, St. Petersburg, Russia.
Objective: To analyze the efficacy and tolerability of aceclofenac in the treatment of patients with acute non-specific musculoskeletal pain in the lower back (ANBP) compared with other NSAIDs (dexketoprofen, nimesulide and lornoxicam), as well as to assess the impact of NSAIDs therapy on the relative risk of recurrence and chronicity of this pathology.
Material And Methods: The study involved 80 patients (47 women and 33 men), average age 52.6 [47.
[The efficacy and tolerability of tolperisone hydrochloride various regimens in the treatment of patients with acute musculoskeletal low back pain].
Zh Nevrol Psikhiatr Im S S Korsakova
October 2024
Clinical Hospital of St. Luka, St-Petersburg, Russia.
Article Synopsis
- The study aimed to evaluate how effective and tolerable different regimens of tolperisone hydrochloride (TH) are for treating acute nonspecific lower back pain (ALBP).
- 90 patients were divided into two groups: one received TH in sustained release form with basic treatment, while the other received TH intramuscularly for 5 days followed by sustained release, with the study lasting 30 days.
- Results showed that group 2 had better pain control for moderate and severe pain over 30 days, improved range of motion, and high therapy adherence, with no major side effects reported.
[The optimization of differential diagnosis and treatment of cervical radiculopathy (SHERPA study)].
Zh Nevrol Psikhiatr Im S S Korsakova
October 2020
Clinical Hospital of St. Luka, St-Petersburg, Russia.
Objective: To improve the algorithm of differential diagnosis and complex treatment of patients with CR.
Material And Methods: Forty-two patients with CR were divided into 2 groups. Patients of the first group (=21) received basic treatment (NSAID, myorelaxants, local injections with glucocorticoids (on demand), B vitamins and non-pharmacological methods) and the anticholinesterase drug ipidacrine.